secwatch.observer — SEC 8-K summary
======================================

Issuer:     CURIS INC (CRIS)
CIK:        0001108205
Form:       8-K
Filed at:   2021-12-06T23:59:59+00:00
Accession:  0001193125-21-348468
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Curis appoints Dr. John A. Hohneker to Board of Directors
---------------------------------------------------------

- Dr. Hohneker elected as Class II director on Dec 2, 2021, term until 2022 annual meeting.
- Receives standard non-employee director compensation: one-time option for 25,000 shares vesting over 4 years.
- Brings 30 years of drug development experience; former President/CEO of Anokion and President of R&D at FORMA Therapeutics.
- Expected to help advance CA-4948 (IRAK4 inhibitor) toward potential approval and commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1108205/000119312521348468/0001193125-21-348468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1108205/000119312521348468/d270245d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-348468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer